AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15563344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive activity
Number of subjects: 96
Study 15563344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 11251924 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline contrast sonohysterography (SCSH)
Number of subjects: 233
Study 9394856 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole, 1 mg once daily, orally
Number of subjects: 0
Study 9394856 — intervention group
Group type: COMPARATOR
Intervention: Formestane, 250 mg every 2 weeks, intramuscularly
Number of subjects: 0
Study 7896425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan (CU) dialyzer
Number of subjects: 234
Study 7896425 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophane (HE) dialyzer
Number of subjects: 234
Study 7896425 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide (PA) dialyzer
Number of subjects: 234
Study 7896425 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood-flow (Qb)
Number of subjects: 234
Study 7896425 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood-flow (Qb)
Number of subjects: 234
Study 2446082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 310
Study 2446082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 30040023 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone inclinometer application on iPhone 6 (IP)
Number of subjects: 38
Study 30040023 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone inclinometer application on Android (AN)
Number of subjects: 38
Study 30040023 — intervention group
Group type: COMPARATOR
Intervention: Comparison of average peak and total UCROM between devices
Number of subjects: 38
Study 28931197 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 0.4 mg/kg/day for 4 weeks, tapered to 0.2 mg/kg/day for 2 months, and to 0.1 mg/kg/day for the last 2 months (Group A)
Number of subjects: 60
Study 28931197 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone tapered within 2 months (Group B)
Number of subjects: 60
Study 25348255 — intervention group
Group type: EXPERIMENTAL
Intervention: LY500307 1 mg
Number of subjects: 414
Study 25348255 — intervention group
Group type: EXPERIMENTAL
Intervention: LY500307 3 mg
Number of subjects: 414
Study 25348255 — intervention group
Group type: EXPERIMENTAL
Intervention: LY500307 10 mg
Number of subjects: 414
Study 25348255 — intervention group
Group type: EXPERIMENTAL
Intervention: LY500307 25 mg
Number of subjects: 414
Study 25348255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study 23989256 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate (1.0 mg daily)
Number of subjects: 256
Study 23989256 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (daily treatment combined with 1000 IU ergocalciferol and 1200 mg elemental calcium)
Number of subjects: 256
Study 21341397 — intervention group
Group type: COMPARATOR
Intervention: S-equol (10-320 mg single dose)
Number of subjects: 101
Study 21341397 — intervention group
Group type: COMPARATOR
Intervention: S-equol (10-160 mg, BID for 14 days)
Number of subjects: 101
Study 21341397 — intervention group
Group type: COMPARATOR
Intervention: S-equol (20 mg single dose with food)
Number of subjects: 101
Study 21341397 — intervention group
Group type: COMPARATOR
Intervention: S-equol (various doses)
Number of subjects: 101
Study 21341397 — intervention group
Group type: COMPARATOR
Intervention: S-equol (320 mg single dose)
Number of subjects: 101
Study 19489805 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual educational intervention about infant sleep position (supine position)
Number of subjects: 228
Study 19489805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 228
Study 17893573 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol‐remifentanil (T group; n=80 patients)
Number of subjects: 162
Study 17893573 — intervention group
Group type: COMPARATOR
Intervention: sevoflurane‐fentanyl (S group; n=82 patients)
Number of subjects: 162
Study 17893573 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study 15310633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone 10 mg
Number of subjects: 120
Study 15310633 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 3 microg.kg(‐1)
Number of subjects: 120
Study 15310633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11402752 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0
Study 8995995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (5 mg) - single dose
Number of subjects: 8
Study 8995995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (5 mg) - double dose
Number of subjects: 8
Study 8995995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8355469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (15 g/day)
Number of subjects: 26
Study 8355469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 26
Study 3117876 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (150 mg)
Number of subjects: 50
Study 3117876 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg)
Number of subjects: 50
Study 29906273 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations ≥60 ng/ml
Number of subjects: 5038
Study 29906273 — intervention group
Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D concentrations <20 ng/ml
Number of subjects: 5038
Study 28868878 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen, liver and kidney-strengthening formula combined with polyethylene glycol interferon α‐2a (or α‐2b)
Number of subjects: 126
Study 28868878 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol interferon α‐2a (or α‐2b)
Number of subjects: 126
Study 24814304 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall with EM (eye movements)
Number of subjects: 73
Study 24814304 — intervention group
Group type: COMPARATOR
Intervention: Recall only (without eye movements)
Number of subjects: 73
Study 22777878 — intervention group
Group type: EXPERIMENTAL
Intervention: SWEEP
Number of subjects: 74
Study 22777878 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 74
Study 19664300 — intervention group
Group type: EXPERIMENTAL
Intervention: High-wheat fibre cereal (24 g fibre/d)
Number of subjects: 14
Study 19664300 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre cereal (control)
Number of subjects: 14
Study 18401223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist recommendations to physicians in intervention clinics
Number of subjects: 179
Study 18401223 — intervention group
Group type: COMPARATOR
Intervention: Standard care in control clinics
Number of subjects: 179
Study 16494210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV)
Number of subjects: 120
Study 16494210 — intervention group
Group type: COMPARATOR
Intervention: Intermediate flora (Group II)
Number of subjects: 120
Study 12197862 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy (coping skills training and cognitive therapy)
Number of subjects: 120
Study 12197862 — intervention group
Group type: COMPARATOR
Intervention: Non-specific supportive therapy
Number of subjects: 120
Study 11563413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (1 mg) with Paroxetine (20 mg once daily)
Number of subjects: 12
Study 11563413 — intervention group
Group type: COMPARATOR
Intervention: Rizatriptan (1 mg)
Number of subjects: 12
Study 7554037 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 AUC (ng h ml-1) using a trivariate model: CPT‐11 AUC = 0.820 x C0.5h + 0.402 x C1h + 15.47 x C6h + 928
Number of subjects: 64
Study 7554037 — intervention group
Group type: EXPERIMENTAL
Intervention: SN-38 AUC (ng h ml-1) using a trivariate model: SN‐38 AUC = 4.05 x C0.5h ‐0.81 x C1h + 23.01 x C6h ‐ 69.78
Number of subjects: 64
Study 1446198 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 30
Study 1446198 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 30
Study 6736272 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (plasma levels)
Number of subjects: 0
Study 6736272 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (red blood cell levels)
Number of subjects: 0
Study 6736272 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (plasma/red blood cell ratio)
Number of subjects: 0
Study 30393935 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA plus chemotherapy
Number of subjects: 83
Study 30393935 — intervention group
Group type: COMPARATOR
Intervention: ATRA only
Number of subjects: 83
Study 30393935 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO)
Number of subjects: 83
Study 30393935 — intervention group
Group type: COMPARATOR
Intervention: No arsenic trioxide (no ATO)
Number of subjects: 83
Study 30393935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (ATRA, cytarabine, anthracyclines)
Number of subjects: 83
Study 29450452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus regional hyperthermia
Number of subjects: 341
Study 29450452 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone
Number of subjects: 341
Study 24983200 — intervention group
Group type: EXPERIMENTAL
Intervention: UBV (60 s ultra-brief video on CO-CPR)
Number of subjects: 100
Study 24983200 — intervention group
Group type: COMPARATOR
Intervention: Control (CTR: sat idle for 60 s)
Number of subjects: 100
Study 22825691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2 intravenously over 3 h) plus Carboplatin (AUC 5 intravenously over 30 min)
Number of subjects: 13
Study 22825691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Carboplatin
Number of subjects: 13
Study 20178395 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized letter from a practicing pharmacist containing treatment recommendations for patients with upcoming primary care visits (intervention group, n = 150)
Number of subjects: 346
Study 20178395 — intervention group
Group type: COMPARATOR
Intervention: Usual care without the letters (control group, n = 151)
Number of subjects: 346
Study 20178395 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized letter from a practicing pharmacist (intervention group)
Number of subjects: 346
Study 20178395 — intervention group
Group type: COMPARATOR
Intervention: Usual care without the letters (control group)
Number of subjects: 346
Study 17141481 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Helicobacter pylori treatment (clarithromycin, amoxicillin, lansoprazole)
Number of subjects: 39
Study 17141481 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination (Lactobacillus rhamnosus GG, L. rhamnosus LC705, Propionibacterium freudenreichii ssp. shermanii JS, Bifidobacterium breve Bb99)
Number of subjects: 39
Study 17141481 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative control group
Number of subjects: 39
Study 15657401 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab therapy (standard 4-week courses administered at 6-month intervals)
Number of subjects: 114
Study 15657401 — intervention group
Group type: COMPARATOR
Intervention: Rituximab re-treatment at progression
Number of subjects: 114
Study 12111340 — intervention group
Group type: EXPERIMENTAL
Intervention: Savoxepine
Number of subjects: 87
Study 12111340 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 87
Study 9647677 — intervention group
Group type: EXPERIMENTAL
Intervention: manual line bisection task
Number of subjects: 3
Study 9647677 — intervention group
Group type: EXPERIMENTAL
Intervention: line bisection task by fixation
Number of subjects: 3
Study 9647677 — intervention group
Group type: EXPERIMENTAL
Intervention: tasks with lines with no landmark
Number of subjects: 3
Study 7794307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 3 mg/kg once daily
Number of subjects: 502
Study 7794307 — intervention group
Group type: COMPARATOR
Intervention: Nystatin 50,000 U/kg four times daily
Number of subjects: 502
Study 7794307 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B 25 mg/kg four times daily
Number of subjects: 502
Study 3277911 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY‐046 (400 mg)
Number of subjects: 9
Study 3277911 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY‐046 (600 mg/day for 3 days)
Number of subjects: 9
Study 3277911 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 9
Study 3277911 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg) + OKY‐046
Number of subjects: 9
Study 31650650 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary balloon catheter
Number of subjects: 324
Study 31650650 — intervention group
Group type: COMPARATOR
Intervention: Compression with thorax pressure bandage (Control)
Number of subjects: 324
Study 30203101 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (TA-ER) 32 mg
Number of subjects: 33
Study 30203101 — intervention group
Group type: COMPARATOR
Intervention: Standard triamcinolone acetonide crystalline suspension (TAcs) 40 mg
Number of subjects: 33
Study 28192225 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 73
Study 28192225 — intervention group
Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 73
Study 24373064 — intervention group
Group type: EXPERIMENTAL
Intervention: Interacting with the companion robot, Paro
Number of subjects: 17
Study 24157260 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained AYUSH providers (narrative prevention counseling)
Number of subjects: 554
Study 24157260 — intervention group
Group type: COMPARATOR
Intervention: Untrained providers (standard care)
Number of subjects: 554
Study 24157260 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained AYUSH providers
Number of subjects: 554
Study 24157260 — intervention group
Group type: COMPARATOR
Intervention: Untrained providers
Number of subjects: 554
Study 21146184 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 204
Study 21146184 — intervention group
Group type: COMPARATOR
Intervention: Intensive care alone
Number of subjects: 204
Study 18061001 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiarrhythmic drugs
Number of subjects: 0
Study 16489888 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line filter placement
Number of subjects: 442
Study 16489888 — intervention group
Group type: COMPARATOR
Intervention: No filter placement
Number of subjects: 442
Study 14604933 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld computer clinical decision support tool
Number of subjects: 169
Study 14604933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket card containing guidelines
Number of subjects: 169
Study 14604933 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study 10783213 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillator implantation
Number of subjects: 3559
Study 10783213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital discharge while taking a beta-blocker
Number of subjects: 3559
Study 10783213 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital discharge while taking an angiotensin-converting enzyme inhibitor
Number of subjects: 3559
Study 10783213 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 3559
Study 10783213 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate predictors of worse survival
Number of subjects: 3559
Study 8624314 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive urinary kallikrein to creatinine ratio (IUK:Cr) measured on an untimed urine sample
Number of subjects: 307
Study 8624314 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive urinary kallikrein to creatinine ratio (IUK:Cr) in women who developed proteinuric pre‐eclampsia
Number of subjects: 307
Study 8624314 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive urinary kallikrein to creatinine ratio (IUK:Cr) in women who developed pre‐eclampsia
Number of subjects: 307
Study 8624314 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver-operator characteristics analysis
Number of subjects: 307
Study 1304178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumice prophylaxis with a rubber cup, etched for 30 seconds
Number of subjects: 60
Study 1304178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumice prophylaxis, etched for 60 seconds
Number of subjects: 60
Study 1304178 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/NaF dentifrice prophylaxis, etched for 30 seconds
Number of subjects: 60
Study 1304178 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/NaF dentifrice prophylaxis, etched for 60 seconds
Number of subjects: 60
Study 3886402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine 15 mg/day
Number of subjects: 20
Study 3886402 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 20
Study 30326380 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 0.1 mg kg-1
Number of subjects: 70
Study 30326380 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg kg-1
Number of subjects: 70
Study 30267045 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster Care Group (FCG)
Number of subjects: 220
Study 30267045 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual Group (CAUG)
Number of subjects: 220
Study 27542517 — intervention group
Group type: EXPERIMENTAL
Intervention: ANWR
Number of subjects: 0
Study 27542517 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 24828386 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary LT‐E4 concentrations during a migraine episode
Number of subjects: 64
Study 24828386 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary PG‐F2a concentrations during a migraine episode
Number of subjects: 64
Study 24828386 — intervention group
Group type: COMPARATOR
Intervention: Control group urinary LT‐E4 concentrations
Number of subjects: 64
Study 22483372 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 40
Study 22483372 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study 19685085 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium breve strain Yakult)
Number of subjects: 42
Study 19685085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18940484 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐L pretreatment (epinephrine and lidocaine mixture)
Number of subjects: 29
Study 16088363 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose simvastatin (80 mg/daily)
Number of subjects: 55
Study 16088363 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/daily
Number of subjects: 55
Study 16088363 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg/daily
Number of subjects: 55
Study 16088363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 12017384 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane administration via microporous capillary membrane oxygenator
Number of subjects: 60
Study 12017384 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane administration via diffusion membrane oxygenator
Number of subjects: 60
Study 10080835 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose BCG
Number of subjects: 0
Study 10080835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose BCG
Number of subjects: 0
Study 10080835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose BCG with IFN-alpha
Number of subjects: 0
Study 10080835 — intervention group
Group type: COMPARATOR
Intervention: Normal control individuals
Number of subjects: 0
Study 10080835 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms (High dose BCG, Low dose BCG, Low dose BCG with IFN-alpha)
Number of subjects: 0
Study 10080835 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood lymphocytes from cancer patients
Number of subjects: 0
Study 10080835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical treatment
Number of subjects: 0
Study 7590403 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg zinc as 220 mg zinc sulphate daily for 4 weeks)
Number of subjects: 10
Study 7590403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2073045 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-Ketamine
Number of subjects: 10
Study 2073045 — intervention group
Group type: COMPARATOR
Intervention: Propofol-Fentanyl
Number of subjects: 10
Study 7428446 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoking periods
Number of subjects: 12
Study 7428446 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation
Number of subjects: 12
Study 31761416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral superficial cervical plexus block with 10 ml of ropivacaine 0.5%
Number of subjects: 74
Study 31761416 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 74
Study 29771184 — intervention group
Group type: EXPERIMENTAL
Intervention: MWR only
Number of subjects: 109
Study 29771184 — intervention group
Group type: EXPERIMENTAL
Intervention: MWR with motivational beliefs component
Number of subjects: 109
Study 29771184 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control
Number of subjects: 109
Study 27632867 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Program (STP) using elastic bands for 6 weeks
Number of subjects: 39
Study 27632867 — intervention group
Group type: COMPARATOR
Intervention: Regular training (Control Group)
Number of subjects: 39
Study 26177480 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg Advax adjuvant
Number of subjects: 25
Study 26177480 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg Advax adjuvant
Number of subjects: 25
Study 26177480 — intervention group
Group type: COMPARATOR
Intervention: TIV alone
Number of subjects: 25
Study 23572466 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose naltrexone (VLNTX) added to methadone taper
Number of subjects: 174